恩替卡韦联合复方鳖甲软肝片对乙型肝炎患者血清IL-6、IL-8、TNF-α水平影响及肝损伤保护作用研究  

Effect on Serum Levels of IL-6 IL-8 TNF-α and Protective Effects of Liver Injury by Entecavir and Compound Biejia Ruangan Tablets in Hepatitis B Patients

作　　者：柴梅[1] 李同进[1] 曹玉娟[1] 耿彦生[1] 韩东[1] 

机构地区：[1]沧州市传染病医院,河北沧州061000

出　　处：《辽宁中医药大学学报》2016年第3期114-116,共3页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：河北省医学科学研究重点课题(ZL20140004)

摘　　要：目的:探讨恩替卡韦联合复方鳖甲软肝片对乙型肝炎患者血清IL-6、IL-8、TNF-α水平影响及对肝损伤保护作用。方法:选取我院收治的乙型肝炎患者124例,根据治疗方法不同分为两组,每组各62例,其中对照组62例,予常规的保肝治疗,实验组在对照组的基础上实施恩替卡韦联合复方鳖甲软肝片治疗。治疗后观察并比较两组患者的临床疗效,血清IL-6、IL-8、TNF-α水平,肝功能情况以及肝纤维化情况。结果:与对照组相比较,实验组的临床疗效显著改善(P<0.05),血清IL-6、IL-8、TNF-α水平显著改善(P<0.05),肝功能明显好转(P<0.05),肝纤维情况明显改善(P<0.05),差异均有统计学意义。结论:恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎患者能够改善血清IL-6、IL-8、TNF-α水平以及肝功能,降低肝纤维化的发生,减轻肝损伤,起到保护肝脏的作用,值得在临床推广使用。Objective：To investigate the effect on serum levels of IL-6,IL-8,TNF-α and protective effects of liver injury by entecavir and Compound Biejia Ruangan Tablets in Hepatitis B patients. Methods：124 patients with Hepatitis B from our hospital were selected and divided into the control group 62 cases and the experiment group 62 cases by different treatment. The control group were treated by treatment of liver,the experiment were treated on the bases of the control group with the entecavir and Compound Biejia Ruangan Tablets. The clinical curative effect,serum IL-6,TNF-α,IL-8,liver function and liver fibrosis were observed and compared after treatment. Result：Compared with the control group,the clinical curative effect were better（P〈0.05）,the serum levels of IL-6,IL-8 and TNF-α were better（P〈0.05）,the liver function were better（P〈0.05）,the liver fiber were better（P〈0.05）. Conclusion：Entecavir and Compound Biejia Ruangan Tablets treatment of hepatitis B patients can improve the serum IL-6,IL-8 and TNF-α levels,and liver function,reduce the occurrence of liver fibrosis,reduce liver damage,play a role in the protection of the liver,and is worth popularizing in clinical use.

关 键 词：恩替卡韦 乙型肝炎 复方鳖甲软肝片 

分 类 号：R512.62[医药卫生—内科学]